<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony DeSantis, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H507639825"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Current treatments for type 2 diabetes have centered on increasing insulin availability (either through direct insulin administration or through agents that promote insulin secretion), improving sensitivity to insulin, delaying the delivery and absorption of carbohydrate from the gastrointestinal tract, or increasing urinary glucose excretion. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce blood glucose by increasing urinary glucose excretion.</p><p>This topic will review the mechanism of action and therapeutic utility of SGLT2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. The initial management of hyperglycemia in adults with type 2 diabetes, the factors involved in the selection of medications for the management of persistent hyperglycemia, and the use of SGLT2 inhibitors for the treatment of diabetic kidney disease and the management of heart failure are presented separately. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120430 utd-content-129531">(Related Pathway(s):  <a class="utd-content-120430" href="/pathway/120430?topicRef=109245&amp;source=see_link">Diabetes: Initial therapy for non-pregnant adults with type 2 DM</a> and  <a class="utd-content-129531" href="/pathway/129531?topicRef=109245&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p class="headingAnchor" id="H4291761945"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The SGLT2 is expressed in the proximal tubule and mediates reabsorption of approximately 90 percent of the filtered glucose load. SGLT2 inhibitors promote the renal excretion of glucose and thereby modestly lower elevated blood glucose levels in patients with type 2 diabetes. The ability to lower blood glucose and glycated hemoglobin (A1C) levels is limited by the filtered load of glucose and the osmotic diuresis that is caused by this therapy. Moreover, although the currently developed SGLT2 inhibitors almost completely block proximal tubular glucose reabsorption, the measured inhibition is less than 50 percent based on urine glucose excretion.</p><p>SGLT2 inhibitors only lower plasma glucose levels by blocking reabsorption of filtered glucose, which falls as plasma levels fall. Thus, they do not usually cause hypoglycemia in the absence of therapies that otherwise cause hypoglycemia. SGLT2 inhibitors modestly decrease blood pressure and weight [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3276743239"><span class="h1">SUGGESTED APPROACH TO THE USE OF SGLT2 INHIBITORS</span></p><p class="headingAnchor" id="H1206846170"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>SGLT2 inhibitors are not considered as initial therapy for the majority of patients with type 2 diabetes. Initial therapy in most patients with type 2 diabetes should begin with diet, body weight reduction, exercise, and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (in the absence of contraindications). (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p>In patients with comorbid cardiovascular or kidney disease, many SGLT2 inhibitors have demonstrated benefit for cardiovascular and kidney outcomes (see <a class="local">'Cardiovascular effects'</a> below and <a class="local">'Kidney outcomes'</a> below). However, SGLT2 inhibitors confer only modest improvement in glycemia and are costly, and long-term safety data on the effects of prolonged glucosuria are lacking. In addition, there are insufficient data on cardiovascular outcomes in individuals with diabetes but without overt cardiovascular or kidney disease. All of these factors must be recognized when considering combination therapy for monotherapy failure. (See  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p>SGLT2 inhibitors have therapeutic utility in the following settings (the specific drugs listed have been demonstrated to have significant beneficial effects in placebo-controlled clinical trials) [<a href="#rid2">2-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with overt atherosclerotic cardiovascular disease (CVD) not reaching glycemic goals with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and lifestyle modifications (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, and <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, but not <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with heart failure not reaching glycemic goals with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and lifestyle modifications (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, and <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To reduce decline in estimated glomerular filtration rate (eGFR) in patients with eGFR &lt;90 mL/min/1.73 m<sup>2</sup> (<a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a> [<a href="#rid7">7</a>]). (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As a third-line agent in patients not meeting glycemic goals on two oral agents (eg, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and sulfonylurea) if for some reason combination metformin and insulin is not a therapeutic option</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As a third-line agent in patients not meeting glycemic goals on <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and insulin therapy, in whom glucagon-like peptide 1 (GLP-1) receptor agonists are contraindicated and increasing insulin dosing would lead to weight gain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As a second agent in patients with inadequate glycemic control on <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> who are unwilling or unable to consider injection therapy and in whom weight gain or risk of hypoglycemia is a significant issue</p><p></p><p>Regardless of the initial response to therapy, the natural history of most patients with type 2 diabetes is for blood glucose concentrations to rise gradually with time. Thus, most patients require additional therapy (addition of a second oral or injectable agent, including insulin, or switch to insulin). The long-term benefits and risks of using one combination over another are unknown. There is a paucity of high-quality, head-to-head drug comparison trials and trials with important clinical endpoints, such as effects on microvascular and macrovascular complications and mortality [<a href="#rid8">8</a>]. The choice of therapy should be individualized based upon patient characteristics, preferences, and costs  (<a class="graphic graphic_table graphicRef56876" data-inline-graphics="56876" href="/d/graphic/56876.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H503705899"><span class="h2">Contraindications and precautions</span><span class="headingEndMark"> — </span>SGLT2 inhibitors should not be used specifically for the treatment of hyperglycemia in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Type 2 diabetes and eGFR &lt;45 mL/min/1.73 m<sup>2</sup> (<a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>), or &lt;30 mL/min/1.73 m<sup>2</sup> (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">bexagliflozin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Prior diabetic ketoacidosis (DKA)</p><p></p><p>SGLT2 inhibitors have less glycemic benefit in patients with more severe kidney disease at initiation, and for the <strong>treatment of hyperglycemia</strong>, SGLT2 inhibitors are not recommended for initiation in patients with eGFR thresholds as described immediately above. For the <strong>treatment of kidney disease</strong>, however, some SGLT2 inhibitors have established benefits for kidney protection when initiated below these thresholds [<a href="#rid9">9</a>]. We favor an individualized approach to initiation of SGLT2 inhibitor therapy that weighs the relative benefits of these agents, including their demonstrated kidney protective effects, against the potential risks. Treatment of kidney disease is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p>SGLT2 inhibitors have been associated with the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Genitourinary tract bacterial and yeast infections. Patients should be counseled about the signs and symptoms of genitourinary infections and notify their provider at symptom onset. Patients with recurrent, severe, or difficult to treat infections should discontinue SGLT2 inhibitor therapy and avoid future use. (See <a class="local">'Genitourinary tract'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone loss and fracture. SGLT2 inhibitors have been associated with fracture risk in some, but not all, studies. Fracture risk might be a consequence of falls related to SGLT2 inhibitor-mediated reductions in blood pressure rather than a direct impact on skeletal physiology. SGLT2 inhibitors should be used with caution in those at risk for falls and fracture. (See <a class="local">'Skeletal fragility'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild volume loss. Patients should be aware of possible side effects due to volume loss (eg, lightheadedness, dizziness, nausea). Blood pressure and kidney function should be monitored. Proactive modification of blood pressure medications should be considered prior to SGLT2 inhibitor initiation. SGLT2 inhibitors should be withheld during times of volume loss or hypoperfusion (diarrhea, sepsis) and restarted only once the patient has recovered. (See <a class="local">'Pretreatment evaluation'</a> below and <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower extremity infection and amputation. SGLT2 inhibitors are associated with a small risk of lower extremity infection and amputation. They should be used with caution in patients with risk factors for foot ulceration (eg, neuropathy, foot deformity, vascular disease, and/or history of previous foot ulceration). Patients should be instructed to perform daily foot examination and should undergo routine examination by their provider. (See <a class="local">'Amputations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DKA. SGLT2 inhibitors increase risk of DKA. Patients should be counseled about symptoms of DKA (eg, fatigue, myalgias, nausea, and emesis) and when to perform urine ketone monitoring. SGLT2 inhibitors should be withheld during times of increased DKA risk (eg, infection, hospitalization, or surgery) and restarted only once the patient has recovered. The benefits and risks of therapy should be carefully assessed in individuals with factors predisposing to DKA (eg, ketosis-prone type 2 diabetes, pancreatic insufficiency, drug or alcohol abuse disorder, ketogenic diets), and SGLT2 inhibitors should be avoided in individuals with a history of DKA. (See <a class="local">'Diabetic ketoacidosis'</a> below.)</p><p></p><p>Since SGLT2 inhibitors can cause a mild degree of dehydration, they should be used with caution in conjunction with other medications that predispose to acute kidney injury (nonsteroidal anti-inflammatory drugs [NSAIDs], angiotensin-converting enzyme [ACE] inhibitors/angiotensin II receptor blockers [ARBs], diuretics) and comorbidities that might predispose to acute kidney injury (hypovolemia, heart failure, liver injury). (See <a class="local">'Dosing'</a> below and <a class="local">'Acute kidney injury'</a> below.)</p><p class="headingAnchor" id="H4225147499"><span class="h2">Choice of therapy</span><span class="headingEndMark"> — </span>There are many different medications for patients who are not meeting glycemic goals after initial therapy with lifestyle intervention and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>. The factors involved in the selection of a particular class of medication for combination therapy is reviewed in detail separately (see  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a>). When a decision has been made to use an SGLT2 inhibitor, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>, and <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">bexagliflozin</a> are available options.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with atherosclerotic CVD</strong> – When a decision has been made to use an SGLT2 inhibitor in a patient with type 2 diabetes and a prior history of atherosclerotic CVD, we suggest <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, rather than another SGLT2 inhibitor. This suggestion is based on the results of the empagliflozin and cardiovascular outcomes study [<a href="#rid4">4</a>]. Although <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> also showed cardiovascular benefits, there was an increase in the risk of lower limb amputations and fractures in canagliflozin-treated patients that was not observed in trials of empagliflozin or <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>. (See <a class="local">'Cardiovascular effects'</a> below and <a class="local">'Amputations'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with heart failure or kidney disease</strong> – In patients with type 2 diabetes and heart failure or kidney disease, all SGLT2 inhibitors have shown salutary effects; choice of agent is primarily dictated by provider preference, insurance formulary restrictions, drug-specific labeling regarding use with varying degrees of kidney function, and cost. (See <a class="local">'Cardiovascular effects'</a> below and <a class="local">'Kidney outcomes'</a> below and <a class="local">'Contraindications and precautions'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without cardiovascular or kidney disease</strong> – In patients without cardiovascular or kidney disease, choice of SGLT2 inhibitor is often dictated by cost and insurer formulary preference, as the published trials have not revealed any substantial differences with regard to A1C lowering, weight reduction, or risk for mycotic infections (see <a class="local">'Clinical outcomes'</a> below).</p><p></p><p>There are no trials directly comparing the individual SGLT2 inhibitors. In network meta-analyses, placebo-corrected A1C reductions for monotherapy and dual therapy ranged from approximately 0.6 to 0.9 and 0.3 to 0.6 percentage points, respectively [<a href="#rid10">10,11</a>]. <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">Canagliflozin</a> 300 mg reduced A1C to a slightly greater extent than <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> 10 mg or <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> 25 mg (mean difference -0.2 percentage points) [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H897940182"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Prior to starting an SGLT2 inhibitor, volume status and kidney function (serum creatinine with eGFR) should be assessed. Hypovolemia should be corrected prior to initiating an SGLT2 inhibitor. Diuretics and blood pressure medications may require dose adjustment prior to the use of SGLT2 inhibitors. Liver function should be assessed prior to initiation of <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> or <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>. Patients at risk for falls and fracture may benefit from assessment of bone density. (See  <a class="medical medical_review" href="/d/html/3012.html" rel="external">"Falls in older persons: Risk factors and patient evaluation", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Assessment of fracture risk'</a>.)</p><p>To reduce the risk of hypoglycemia, patients using insulin or insulin secretagogues (sulfonylureas, glinides) may require a dose reduction with initiation of SGLT2 inhibitors.</p><p class="headingAnchor" id="H4130796457"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>SGLT2 inhibitors have less glycemic benefit in patients with more severe kidney disease at initiation, and for the specific treatment of hyperglycemia, SGLT2 inhibitors are not recommended for initiation in patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup> (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">bexagliflozin</a>) or &lt;45 mL/min/1.73 m<sup>2</sup> (<a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>).</p><p>After initial therapy, the decision to escalate the dose (typically after 4 to 12 weeks) should be based on tolerance, adverse effects, and glycemic assessment (home glucose monitoring and/or A1C). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Canagliflozin</strong> – <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">Canagliflozin</a> is taken orally before the first meal of the day [<a href="#rid12">12,13</a>]. The initial dose is 100 mg once daily, and it can be increased to 300 mg daily to achieve glycemic goals. In patients with moderate kidney impairment (eGFR 30 to 59 mL/min/1.73 m<sup>2</sup>), the dose should not exceed 100 mg daily. Canagliflozin should not be given to patients with severe hepatic impairment. No dose adjustment is needed in patients with mild or moderate hepatic impairment [<a href="#rid12">12,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapagliflozin</strong> – <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">Dapagliflozin</a> (10 mg once daily) can be taken any time of day with or without food. It is not recommended for use in patients with active bladder cancer [<a href="#rid15">15,16</a>]. For patients with severely reduced liver function, a starting dose of 5 mg is recommended. There is limited experience in patients with severe hepatic impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empagliflozin</strong> – <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">Empagliflozin</a> is taken orally once daily in the morning with or without food [<a href="#rid17">17</a>]. The initial dose is 10 mg daily, and it can be increased to 25 mg once daily to achieve glycemic goals. In patients taking empagliflozin who have an eGFR 30 to 45 mL/min/1.73 m<sup>2</sup>, the dose should not exceed 10 mg. Empagliflozin may be used in patients with hepatic impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ertugliflozin</strong> – <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">Ertugliflozin</a> is taken once daily in the morning with or without food [<a href="#rid18">18</a>]. The initial dose is 5 mg once daily and may be increased to a maximum dose of 15 mg once daily to achieve glycemic goals. In patients taking ertugliflozin who have a persistent fall in eGFR &lt;45 mL/min/1.73 m<sup>2</sup>, it should be discontinued if hyperglycemia management was the only reason for therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bexagliflozin</strong><strong> </strong>– <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">Bexagliflozin</a> (20 mg once daily) is taken orally in the morning with or without food [<a href="#rid19">19</a>]. It should not be initiated in individuals with an eGFR &lt;30 mL/min/1.73 m<sup>2 </sup>or in those with severe hepatic impairment due to lack of clinical data in these populations. No dose adjustments are needed for milder degrees of kidney or liver impairment. </p><p></p><p class="headingAnchor" id="H3547703127"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>In addition to glycemic indices (A1C, fasting blood glucose), kidney function and volume status (blood pressure) should be monitored during SGLT2 inhibitor treatment. SGLT2 inhibitors may need to be withheld in some settings.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney function</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>eGFR &gt;60 mL/min/1.73 m<sup>2</sup> – We measure serum creatinine after three months and, if stable, then annually or as clinically indicated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>eGFR between 30 and 60 mL/min/1.73 m<sup>2</sup> – We measure serum creatinine every three months or as clinically indicated.</p><p></p><p class="bulletIndent1">An initial short-term decrease in eGFR (of up to 30 percent) may be seen after starting SGLT2 inhibitor therapy, presumably due to a reduction in glomerular pressure. Following this initial decline, eGFR stabilizes. Greater initial reductions in eGFR warrant discontinuation of SGLT2 inhibitor therapy and evaluation for causes of acute kidney injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic indices </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients taking insulin or insulin secretagogues, SGLT2 inhibitors can increase the risk of hypoglycemia. Patients taking insulin or insulin secretagogues should monitor fasting and pre-meal fingerstick glucose for the first few weeks following initiation or dose escalation of SGLT2 inhibitors. Insulin dosing should be decreased by 10 to 20 percent and insulin secretagogue dosing by 50 percent if blood glucose values &lt;80 mg/dL are measured.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We measure A1C initially every three months until glycemic goals are achieved. We measure A1C at least twice yearly in patients meeting glycemic goals but continue to assess more frequently (quarterly) in patients whose therapy has changed or those who are not meeting glycemic goals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection risk</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients taking SGLT2 inhibitors should be monitored for signs and symptoms of genitourinary tract infections and foot ulceration. We discontinue therapy in patients with frequent bacterial urinary tract infections or genitourinary yeast infections. (See <a class="local">'Contraindications and precautions'</a> above and <a class="local">'Genitourinary tract'</a> below and <a class="local">'Amputations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DKA</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SGLT2 inhibitors can increase the risk of DKA. The absence of substantial hyperglycemia in some individuals delays recognition of the problem by both the patients and the clinicians. Serum ketones should be obtained in any patient with nausea, vomiting, or malaise while taking SGLT2 inhibitors, and patients should be counseled to withhold SGLT2 inhibitor therapy until these symptoms resolve. If a patient develops DKA on SGLT2 inhibitor therapy, we discontinue treatment with this medication class. (See <a class="local">'Diabetic ketoacidosis'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SGLT2 inhibitors also should be held during episodes of acute illness, prolonged fasting, and surgical procedures. An alternative plan for glycemic management should be implemented until the elevated risk of acute kidney injury, organ hypoperfusion, and acidosis subsides.</p><p></p><p class="headingAnchor" id="H1716003727"><span class="h1">CLINICAL OUTCOMES</span></p><p class="headingAnchor" id="H3818284521"><span class="h2">Glycemic efficacy</span><span class="headingEndMark"> — </span>SGLT2 inhibitors are relatively weak glucose-lowering agents, with mean reductions in A1C compared with placebo ranging between 0.4 to 1.1 percent depending on baseline level of hyperglycemia. They have been studied as monotherapy and in combination with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, sulfonylureas, <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a>, <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>, and insulin [<a href="#rid1">1,20-27</a>]. <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">Dapagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>, and <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> are available in Europe and the United States [<a href="#rid16">16,28-30</a>]. <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">Bexagliflozin</a> is available in the United States. Other SGLT2 inhibitors are in development.</p><p>In meta-analyses of clinical trials comparing SGLT2 inhibitors with placebo or active comparators (<a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, sulfonylurea, dipeptidyl peptidase 4 [DPP-4] inhibitors, insulin), SGLT2 inhibitors compared with placebo reduced A1C by approximately 0.5 to 0.7 percentage points (mean difference versus active comparators -0.06 to -0.13 percent) [<a href="#rid20">20,31-33</a>].</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 52-week, double-blind trial, 814 patients with type 2 diabetes and inadequate glycemic management with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (mean A1C 7.7 percent) were randomly assigned to <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> or <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a> [<a href="#rid34">34</a>]. The mean reduction in A1C was similar in both groups (-0.52 percentage points). Dapagliflozin reduced body weight (-3.2 versus +1.2 kg with glipizide) and produced fewer severe (requiring assistance) hypoglycemic episodes (0 versus 0.7 percent with glipizide).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, 808 patients with type 2 diabetes mellitus and inadequate glycemic management with insulin and up to two oral agents were randomly assigned to <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> (2.5, 5, or 10 mg once daily) or placebo [<a href="#rid35">35</a>]. After 24 weeks, A1C decreased by 0.79 to 0.96 percentage points with dapagliflozin compared with 0.39 percentage points with placebo (mean difference -0.40 to -0.57 percentage points in the 2.5 to 10 mg groups, respectively). Daily insulin dose decreased by 0.63 to 1.95 units with dapagliflozin and increased by 5.65 units with placebo. Dapagliflozin reduced body weight (-0.92 to -1.61 versus +0.43 kg with placebo). The rate of hypoglycemic episodes was higher in the dapagliflozin group (56.6 versus 51.8 percent with placebo).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 52-week, double-blind trial, 755 patients with type 2 diabetes and inadequate glycemic management with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> plus a sulfonylurea (mean A1C 8.1 percent) were randomly assigned to <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> (300 mg daily) or <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a> (100 mg daily) [<a href="#rid36">36</a>]. The mean reduction in A1C from baseline was greater with canagliflozin than sitagliptin (least squares mean change -1.03 and -0.66 percentage points, respectively). Canagliflozin reduced body weight (-2.5 versus 0.3 percent change from baseline) and systolic blood pressure (-5.1 versus 0.99 mmHg) compared with sitagliptin. Although the overall incidence of adverse events was similar for the two drugs, the frequency of genital fungal infections was almost sixfold higher with canagliflozin. The overall results of this study must be viewed cautiously as almost 40 percent of the subjects did not complete the year-long study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 52-week, double-blind trial, 1452 patients with type 2 diabetes and inadequate glycemic management with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (mean A1C 7.8 percent) were randomly assigned to <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a> (titrated based upon blood glucose, median dose 5.6 mg daily) or <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> (100 or 300 mg daily) [<a href="#rid37">37</a>]. The mean reduction in A1C from baseline was similar in the glimepiride and lower-dose canagliflozin groups (-0.81 and -0.82 percentage points, respectively) and better by 0.1 A1C percentage point in the higher-dose canagliflozin group (-0.93 percentage points). The proportion of patients achieving an A1C &lt;7 or &lt;6.5 percent was similar among groups (approximately 56 and 31 percent of patients, respectively). Canagliflozin reduced body weight (-4.2 to -4.4 kg versus +0.8 kg with glimepiride) and caused less frequent severe hypoglycemia (&lt;1 versus 3 percent with glimepiride) but more frequent genital yeast infections in both women and men (in women, 11 to 14 percent versus 2 percent with glimepiride; in men, 7 to 8 percent versus 1 percent with glimepiride).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 52-week trial, patients with type 2 diabetes and inadequate glycemic management on multidose insulin and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (mean A1C 8.3 percent) were randomly assigned to <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> (10 or 25 mg once daily) or placebo [<a href="#rid22">22</a>]. The reduction in A1C was greater with empagliflozin (-1.18, -1.21, and -0.81 percentage points for empagliflozin 10 mg, empagliflozin 25 mg, and placebo, respectively). Compared with placebo, empagliflozin reduced insulin doses by 9 to 11 units per day and body weight by 2.4 kg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 52-week, double-blind trial, 1326 patients with type 2 diabetes and inadequate glycemic management with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (mean A1C 7.8 percent) were randomly assigned to <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a> (5 or 15 mg daily) or <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a> (titrated based upon blood glucose, median dose 3 mg daily) [<a href="#rid25">25</a>]. The mean reduction in A1C from baseline with ertugliflozin 15 mg daily was noninferior to glimepiride (-0.6 and -0.7 percentage points, respectively). Ertugliflozin caused less frequent severe hypoglycemia (&lt;0.2 compared with 2.3 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 24-week trial, 386 patients with type 2 diabetes inadequately treated with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> monotherapy (mean A1C 8 percent) were randomly assigned to <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">bexagliflozin</a> (20 mg daily) or <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a> (100 mg daily) [<a href="#rid38">38</a>]. The mean reduction in A1C was comparable in the bexagliflozin and sitagliptin groups (mean change from baseline -0.74 versus -0.82 percentage points, respectively). In a trial in 288 patients with type 2 diabetes, treatment with bexagliflozin monotherapy for 96 weeks led to a greater reduction in A1C than treatment with placebo (-0.55 percentage points versus +0.53 percentage points, respectively) [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H3125494270"><span class="h2">Cardiovascular effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atherosclerotic cardiovascular disease (CVD) and cardiovascular mortality</strong> – <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">Empagliflozin</a> and <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> have been shown to decrease atherosclerotic cardiovascular morbidity and mortality in patients with type 2 diabetes and overt CVD [<a href="#rid4">4,5</a>]. In the primary analysis, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> did not appear to reduce atherosclerotic cardiovascular morbidity or cardiovascular mortality [<a href="#rid3">3</a>]; however, it decreased cardiovascular outcomes in a subanalysis of the primary trial confined to participants with prior myocardial infarction [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure </strong>– SGLT2 inhibitors as a class reduce risk of hospitalization for heart failure in adults with diabetes and high CVD risk irrespective of a prior diagnosis of heart failure [<a href="#rid41">41-44</a>]. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Therapy for patients with HF and elevated BNP'</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.)</p><p></p><p>The cardiovascular trials to date have been carried out in very high-risk populations to increase the hazard rate for major CVD events and complete the studies in a relatively brief period. Of note, compared with the <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> and <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> trials, the <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> trial had a lower fraction of participants with established CVD and a greater proportion of patients with multiple risk factors for CVD (multiple risk factors in 60 percent compared with 0 and 34 percent in the empagliflozin and canagliflozin trials, respectively). However, the <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a> cardiovascular trial only included patients with established CVD and did not show superior benefit in the composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) [<a href="#rid45">45</a>]. These differences in patient populations likely contribute to the discrepant effects of SGLT2 inhibitors on atherosclerotic CVD outcomes across trials. The cardiovascular effects of <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">bexagliflozin</a> are least established, and results from a cardiovascular outcome trial are pending [<a href="#rid46">46</a>]. Several meta-analyses have been performed to better establish the cardiovascular effects of SGLT2 inhibitors as a class [<a href="#rid41">41-43,47</a>].</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In meta-analyses of the three major CVD outcome trials (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>), SGLT2 inhibitors compared with placebo reduced the risk of major adverse cardiovascular events (86.9 versus 99.6 events per 1000 patient-years, hazard ratio [HR] 0.89, 95% CI 0.83-0.96) and a composite outcome of CV death or hospitalization for heart failure (48.2 versus 65.6 events per 1000 patient-years, HR 0.77, 95% CI 0.71-0.84) [<a href="#rid41">41,47</a>]. The clinical benefit of the SGLT2 inhibitors for reducing the risk of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) was limited to those patients with established atherosclerotic CVD, with no benefit in those with multiple risk factors for CVD [<a href="#rid41">41,47</a>]. In contrast to the findings for major adverse cardiovascular events, the meta-analyses showed a reduction in hospitalization for heart failure with use of SGLT2 inhibitors regardless of the presence of established atherosclerotic CVD or heart failure at baseline. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent meta-analysis of five trials comparing an SGLT2 inhibitor (<a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>, <a class="drug drug_general" data-topicid="141599" href="/d/drug information/141599.html" rel="external">sotagliflozin</a>) with placebo in people with diabetes and established CVD, SGLT2 inhibitors reduced the risk of cardiovascular mortality (72 versus 86 per 1000 persons; odds ratio [OR] 0.82, 95% CI 0.70-0.95) and heart failure hospitalizations (78 versus 116 per 1000 persons, OR 0.65, 95% CI 0.59-0.71) [<a href="#rid42">42</a>]. SGLT2 inhibitors did not reduce the risk of fatal or nonfatal myocardial infarction (54 versus 56 per 1000 persons; OR 0.97, 95% CI 0.84-1.12) or stroke (34 versus 31 per 1000 persons; OR 1.12, 95% CI 0.92-1.36). Sotagliflozin is a dual SGLT1/SGLT2 inhibitor that has regulatory approval in the United States for cardiovascular risk reduction but not glucose lowering.</p><p></p><p>Until large, prospective, randomized trials are conducted, it is unknown whether <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, or other SGLT2 inhibitors will have similar cardioprotective effects in the majority of persons with type 2 diabetes who do not have overt CVD. </p><p>The individual trials included in these meta-analyses are reviewed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empagliflozin</strong> – In a trial designed specifically to evaluate cardiovascular morbidity and mortality in patients with type 2 diabetes and established CVD, 7028 patients with type 2 diabetes (mean A1C approximately 8 percent) and CVD were randomly assigned to <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> (10 or 25 mg) or placebo once daily [<a href="#rid4">4</a>]. The majority of patients were taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, antihypertensives, and lipid-lowering agents (equally distributed in both groups) to control blood glucose, blood pressure, and cholesterol, respectively. Approximately 48 percent of patients in each group were taking insulin.</p><p></p><p class="bulletIndent1">After three years, the primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in fewer patients assigned to <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> than to placebo (10.5 versus 12.1 percent; HR pooled analysis 0.86, 95% CI 0.74-0.99). The findings were driven by a significant reduction in risk of death from cardiovascular causes (3.7 versus 5.9 percent with placebo; HR 0.62, 95% CI 0.49-0.77). There was no significant difference in the occurrence of the individual components of nonfatal myocardial infarction (4.5 versus 5.2 percent with placebo) or nonfatal stroke (3.2 versus 2.6 percent). Findings were similar in the individual empagliflozin dose groups.</p><p></p><p class="bulletIndent1">The rate of hospitalization for heart failure was lower in the <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> group (2.7 versus 4.1 percent in the placebo group). Compared with patients taking placebo, patients taking empagliflozin had lower A1C levels (mean 7.8 versus 8.2 percent) and reductions in body weight, waist circumference, systolic and diastolic blood pressure (with no increase in heart rate), and uric acid. There were small increases in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol in patients taking empagliflozin.</p><p></p><p class="bulletIndent1">In patients with heart failure with reduced ejection fraction (HFrEF), with or without diabetes, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> has been shown to reduce cardiovascular mortality and worsening heart failure [<a href="#rid48">48</a>]. Empagliflozin in the treatment of HFrEF is reviewed separately. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Canagliflozin</strong> – In two trials designed to assess the effects of <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> on cardiovascular, kidney, and safety outcomes in patients with type 2 diabetes and high cardiovascular risk, 10,142 patients (mean A1C 8.2 percent) were randomly assigned to canagliflozin or placebo [<a href="#rid5">5</a>]. The majority of patients were taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, antihypertensives, and lipid-lowering agents (equally distributed in both groups) to manage blood glucose, blood pressure, and cholesterol, respectively. Approximately 50 percent of patients in each group were taking insulin.</p><p></p><p class="bulletIndent1">After a mean follow-up of 3.6 years, the primary outcome, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurred in fewer patients in the <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> group (26.9 versus 31.5 patients per 1000 patient-years, HR 0.86, 95% CI 0.75-0.97). The reductions in the occurrence of the individual components of the composite outcome in those randomized to canagliflozin (11.6 versus 12.8, 9.7 versus 11.6, and 7.1 versus 8.4 patients per 1000 patient-years, respectively) were not statistically significant. The rate of hospitalization for heart failure was lower in the canagliflozin group (5.5 versus 8.7 patients per 1000 patient-years in the placebo group, HR 0.67, 95% CI 0.52-0.87).</p><p></p><p class="bulletIndent1">Compared with patients taking placebo, patients taking <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> had lower A1C levels (mean difference -0.58 percent) and greater reductions in body weight and systolic and diastolic blood pressure.</p><p></p><p class="bulletIndent1">In a subsequent trial designed to primarily evaluate kidney outcomes in patients with type 2 diabetes and nephropathy (mean eGFR 56.2 mL/min/1.73 m<sup>2</sup>, median urinary albumin-to-creatinine ratio 927 [mg/g]), there were similar reductions in cardiovascular events [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Kidney outcomes and the increased risk of amputations in the <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> group are reviewed below. (See <a class="local">'Kidney outcomes'</a> below and <a class="local">'Amputations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapagliflozin</strong> – In a trial designed to assess the effects of <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> on cardiovascular and kidney outcomes, 17,160 patients with type 2 diabetes (mean A1C approximately 8.3 percent) who had or were at risk for CVD were randomly assigned to dapagliflozin (10 mg) or placebo once daily [<a href="#rid3">3</a>]. The majority of patients were taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, antihypertensives, and lipid-lowering agents (equally distributed in both groups) to manage blood glucose, blood pressure, and cholesterol, respectively. Approximately 40 percent of patients in each group were taking insulin.</p><p></p><p class="bulletIndent1">After a median follow-up of 4.2 years, the first primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal ischemic stroke) occurred in 8.8 and 9.4 percent of patients taking <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> and placebo, respectively (HR 0.93, 95% CI 0.84-1.03). Participants who received dapagliflozin had a reduction in the second primary outcome (a composite of cardiovascular death or hospitalization for heart failure), primarily driven by the reduction in hospitalization for heart failure (6.2 versus 8.5 percent with placebo, HR 0.73, 95% CI 0.61-0.88). There was no difference between the two groups in death from any cause (6.2 versus 6.6 percent in the placebo group, HR 0.93, 95% CI 0.82-1.04).</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> trial included enough participants with established cardiovascular disease or multiple risk factors at baseline, randomized to dapagliflozin or placebo, to perform subanalyses within the two groups [<a href="#rid40">40</a>]. Dapagliflozin reduced the two co-primary cardiovascular outcomes in participants with a prior myocardial infarction (15.2 versus 17.8 percent [HR 0.84, 95% CI 0.72-0.99]) but not in those without prior myocardial infarction (7.1 versus 7.1 percent [HR 1.00, 95% CI 0.88-1.13]). In a subsequent exploratory analysis, dapagliflozin also reduced the incidence of atrial fibrillation/atrial flutter adverse events [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">In patients with or without diabetes, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> has been shown to reduce all-cause mortality and heart failure progression in adults with heart failure with reduced ejection fraction (HFrEF) with New York Heart Association functional class II, III, or IV [<a href="#rid50">50</a>]. Dapagliflozin in the treatment of HFrEF is reviewed separately. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ertugliflozin</strong> –<strong> </strong>In a trial designed to evaluate lack of inferiority for composite cardiovascular outcomes, 8246 individuals with type 2 diabetes (mean A1C 8.2 percent) and preexisting CVD were randomly assigned to <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a> (5 or 15 mg) or placebo once daily [<a href="#rid45">45</a>]. The majority of participants were taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (76 percent), and approximately 47 percent of patients were taking insulin. After a mean follow-up of 3.5 years, ertugliflozin treatment did not meet superiority to placebo in the primary composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (11.9 percent in each group [HR 0.97, 95% CI 0.85-1.11]). There was a significant reduction in hospitalization for heart failure with ertugliflozin (2.5 versus 3.6 percent with placebo [HR 0.7, 95% CI 0.54-0.90]).</p><p></p><p>The findings from these studies need to be kept in perspective. The large relative cardiovascular benefit of <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> and <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, while impressive, was in a very high-risk population with established CVD at baseline. Moreover, the absolute risk reduction is approximately 10 to 15 cases per 1000 patient-years, and the benefit in patients taking canagliflozin, in particular, must be balanced with the increased risk of amputations. The difference in glycemia between the treatment groups was minimal, suggesting that non-glycemic drug effects were responsible for the CVD outcomes. The salutary impact of SGLT2 inhibitors on heart failure outcomes seems to be a class effect.</p><p class="headingAnchor" id="H1231659055"><span class="h2">Microvascular outcomes</span></p><p class="headingAnchor" id="H2268566484"><span class="h3">Kidney outcomes</span><span class="headingEndMark"> — </span>SGLT2 inhibitors as a class decrease the risk of kidney disease progression [<a href="#rid44">44,51</a>]. In a meta-analysis of the three major CVD outcome trials, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, and <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> reduced progression of diabetic kidney disease, with a similar effect observed in patients with established atherosclerotic CVD or multiple risk factors for CVD [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a>.)</p><p>Although the benefit was present across all estimated glomerular filtration rates (eGFRs) studied, less benefit was apparent in those with more severe kidney disease at baseline. SGLT2 inhibitors are not recommended for initiation specifically for glucose lowering in patients with eGFR &lt;30 or &lt;45 mL/min/1.73 m<sup>2</sup>, with some differences in each medication depending on the labeling. (See <a class="local">'Contraindications and precautions'</a> above.)</p><p>The mechanism behind the reduction in incident or worsening nephropathy with SGLT2 inhibitors is likely multifactorial but is thought to be largely related to a direct renovascular effect. The relatively brief duration of the studies and modest improvement in glycemia compared with placebo make glucose lowering an unlikely explanation for the reductions in relatively late-stage nephropathy. </p><p>There have been reports of acute kidney injury, some requiring hospitalization and dialysis, in patients taking <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> or <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>. (See <a class="local">'Adverse effects'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empagliflozin</strong> – In the <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> trial described above, which was designed specifically to evaluate cardiovascular morbidity and mortality in patients with type 2 diabetes and established CVD, microvascular disease was a prespecified secondary outcome [<a href="#rid4">4</a>]. The composite microvascular endpoint (the initiation of retinal photocoagulation, vitreous hemorrhage, diabetes-related blindness, or incident or worsening nephropathy) occurred in fewer patients in the empagliflozin group (14 versus 20.5 percent).</p><p></p><p class="bulletIndent1">This reduction was driven entirely by a reduction in incident or worsening nephropathy (defined as progression to macroalbuminuria, doubling of the serum creatinine level, initiation of kidney replacement therapy, or death from kidney disease), which occurred in 12.7 and 18.8 percent of patients in the <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> and placebo groups, respectively (HR 0.61, 95% CI 0.53-0.70) [<a href="#rid52">52</a>]. There were significant reductions in each component of the outcome, except for death from kidney disease. There were three deaths from kidney disease in the empagliflozin group (0.1 percent) and none in the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Canagliflozin</strong> – In the <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> trial (described above) assessing cardiovascular, kidney, and safety outcomes in patients with type 2 diabetes and high cardiovascular risk, progression of albuminuria (a secondary endpoint) occurred less frequently in the canagliflozin group (89.4 versus 128.7 participants per 1000 patient-years in the placebo group, HR 0.73, 95% CI 0.67-0.79) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">In a post hoc exploratory analysis, the composite outcome (sustained 40 percent reduction in estimated glomerular filtration rate (eGFR), need for kidney replacement therapy, or death from kidney-related causes) occurred less frequently in the <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> than placebo group (5.5 versus 9.0 patients per 1000 patient-years, respectively, HR 0.60, 95% CI 0.47-0.77) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">In a subsequent trial specifically designed to evaluate kidney outcomes, 4401 patients with type 2 diabetes and severely increased albuminuria (mean eGFR 56.2 mL/min/1.73 m<sup>2</sup>, median urinary albumin-to-creatinine ratio 927 [mg/g]) were randomly assigned to <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> (100 mg daily) or placebo [<a href="#rid6">6</a>]. The majority of patients were taking insulin and/or <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, with approximately 30 percent taking a sulfonylurea. All patients were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The trial was stopped early for benefit after a median follow-up of 2.6 years. The primary outcome (a composite of end-stage kidney disease [ESKD], doubling of serum creatinine, or death from kidney-related or cardiovascular causes) occurred in a smaller proportion of patients taking canagliflozin (43.2 versus 61.2 events per 1000 patient-years, HR 0.70, 95% CI 0.59-0.82). The effect size was similar across components of the primary outcome, except for kidney disease-related death, which occurred in few patients (two versus five kidney disease-related deaths with placebo). The kidney protective effect of canagliflozin was most pronounced in those with an eGFR between 45 to 60 mL/min/1.73 m<sup>2</sup> at study onset but was seen with eGFR as low as 30 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapagliflozin</strong> – In the <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> trial described above assessing cardiovascular and kidney outcomes in patients with type 2 diabetes who had or were at risk for CVD, there was a reduction in the kidney composite outcome (sustained decrease of 40 percent or more in eGFR to &lt;60 mL/min, new ESKD, or death from kidney-related or cardiovascular causes), which occurred in 4.3 and 5.6 percent of the patients in the dapagliflozin and placebo groups, respectively (HR 0.76, 95% CI 0.67-0.87) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">In a subsequent trial designed to assess kidney outcomes, 4304 individuals with eGFR 25 to 75 mL/min/1.73 m<sup>2</sup> and urine albumin-to-creatinine ratio 200 to 5000 mg/g (median, 950 mg/g) were randomly assigned to <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> (10 mg once daily) or placebo [<a href="#rid2">2</a>]. After a median follow-up of 2.4 years, the composite primary outcome (sustained decline in eGFR of ≥50 percent, ESKD, or death from kidney-related or cardiovascular causes) occurred in fewer patients in the dapagliflozin group (9.2 versus 14.5 percent, HR 0.61, 95% CI 0.51-0.72). The benefit was similar across components of the primary outcome, except for kidney disease-related death, which occurred in few patients (two versus six kidney disease-related deaths with placebo).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ertugliflozin</strong> – In the <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a> trial described above assessing cardiovascular outcomes in patients with type 2 diabetes and preexisting CVD, ertugliflozin treatment led to a nonsignificant reduction in the composite kidney endpoint of death from kidney-related causes, kidney replacement therapy, or doubling of the serum creatinine level (3.2 versus 3.9 percent with placebo [HR 0.81, 95% CI 0.63-1.04]) [<a href="#rid45">45</a>]. Although not statistically significant, the trend is similar to other drugs in the class despite stricter prespecified kidney endpoints.</p><p></p><p class="headingAnchor" id="H1686475765"><span class="h3">Retinopathy outcomes</span><span class="headingEndMark"> — </span>The impact of SGLT2 inhibitor therapy on retinopathy outcomes remains uncertain. In a post hoc analysis of a cardiovascular outcome trial in 7020 participants with type 2 diabetes, participants who were randomly assigned to <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> treatment did not have a significantly lower risk of the composite retinopathy outcome compared with those assigned to placebo (HR 0.78, 95% CI 0.54-1.12) [<a href="#rid53">53</a>]. </p><p>In subsequent meta-analyses of clinical trial data, SGLT2 inhibitors have overall shown no harm for ocular outcomes [<a href="#rid54">54</a>] and a possible benefit for individuals with shorter diabetes duration (&lt;10 years) [<a href="#rid55">55</a>]. In another meta-analysis, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> and <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a> reduced the risk of retinopathy and retinal disease, respectively, compared with controls (placebo or active comparator), whereas <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> increased the risk of vitreous disease compared with placebo [<a href="#rid56">56</a>].</p><p>Observational data support the potential protective effects of SGLT2 inhibitors on retinopathy outcomes in individuals with shorter diabetes duration. In a prospective cohort study in patients with newly diagnosed type 2 diabetes, the incidence of sight-threatening retinopathy was lower among patients taking SGLT2 inhibitors than those taking DPP-4 inhibitors (65,930 patient pairs; adjusted hazard ratio [AHR] 0.57, 95% CI 0.51-0.63), those taking <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> (93,760 patient pairs; AHR 0.75, 95% CI 0.69-0.81), or those taking sulfonylureas (42,121 patient pairs; AHR 0.62, 95% CI 0.53-0.71) [<a href="#rid57">57</a>]. This protective effect was similar for <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, and <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>. Propensity score matching was used to identify patient pairs, and variables included age, sex, smoking status, diabetes duration, other diabetes pharmacotherapy, and comorbid conditions. A major limitation of this clinical data set analysis was the unavailability of A1C or other metrics of glycemia, underscoring the relatively low quality of these observational data.</p><p class="headingAnchor" id="H1096911698"><span class="h2">All-cause mortality</span><span class="headingEndMark"> — </span>SGLT2 inhibitors appear to reduce overall mortality in people with diabetes and established CVD or multiple CVD risk factors [<a href="#rid43">43,44</a>]. In a meta-analysis of five trials comparing an SGLT2 inhibitor (<a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">ertugliflozin</a>, <a class="drug drug_general" data-topicid="141599" href="/d/drug information/141599.html" rel="external">sotagliflozin</a>) with placebo in people with diabetes and CVD, SGLT2 inhibitors reduced the risk of all-cause mortality (96 versus 113 per 1000 persons; OR 0.84, 95% CI 0.74-0.96) [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2325150020"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>SGLT2 inhibitors decrease body weight [<a href="#rid1">1,58</a>]. The weight loss appears to be sustained over time. In a meta-analysis of longer-term trials (one to two years), comparing SGLT2 inhibitors with placebo, SGLT2 inhibitors reduced body weight relative to placebo (mean difference at two years -2.99 kg, 95% CI -3.64 to -2.34) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2276212146"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H3506386806"><span class="h2">Genitourinary tract</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – In clinical trials, SGLT2 inhibitors conferred an approximate two- to fourfold increased incidence of vulvovaginal candidiasis, reported in up to 10 to 15 percent of women [<a href="#rid25">25,59,60</a>]. Similarly, in meta-analyses of trials, SGLT2 inhibitor use also led to a higher rate of vulvovaginal candidal infections (eg, 9.5 versus 2.6 percent in the control groups) [<a href="#rid1">1,20,61</a>]. SGLT2 inhibitors increase the rate of urinary tract infections (8.8 versus 6.1 percent) [<a href="#rid1">1,20</a>]. In addition, the US Food and Drug Administration (FDA) has received reports of potentially fatal:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urosepsis and pyelonephritis [<a href="#rid62">62</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Necrotizing fasciitis of the perineum (Fournier's gangrene) [<a href="#rid63">63-65</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bladder cancer</strong> – In clinical trials, 10 cases of bladder cancer were diagnosed among <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> users, five of which occurred in the first six months of dapagliflozin, a much shorter time interval than would be expected if dapagliflozin promoted tumorigenesis. However, these findings have prompted the FDA to recommend postmarketing surveillance studies [<a href="#rid16">16,66</a>]. There are no long-term safety data with regard to the effects of chronic glucosuria on the urinary tract.</p><p></p><p class="headingAnchor" id="H3144765874"><span class="h2">Hypotension</span><span class="headingEndMark"> — </span>SGLT2 inhibitors cause an osmotic diuresis and intravascular volume contraction. In older patients or in patients taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs), SGLT2 inhibitors may cause symptomatic hypotension [<a href="#rid67">67,68</a>]. Patients should be queried about orthostatic symptoms and instructed to monitor blood pressure, when feasible, during SGLT2 inhibitor initiation. Medications for hypertension might require dose adjustment to reduce risk of hypotension. </p><p class="headingAnchor" id="H2197266214"><span class="h2">Acute kidney injury</span><span class="headingEndMark"> — </span>There have been postmarketing reports of acute kidney injury (some requiring hospitalization and dialysis) in patients taking <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> or <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> [<a href="#rid69">69,70</a>]. Among 101 cases of possible SGLT2-associated acute kidney injury reported to the FDA, approximately one-half occurred within one month of initiating the drug, and most patients improved after the drug was discontinued. Some patients with acute kidney injury may have been volume depleted, hypotensive, or taking other medications that could affect the kidneys. It is unclear whether any of the patients in these reports had preexisting chronic kidney disease.</p><p>In a subsequent analysis of SGLT2 users and nonusers in two different cohorts, the risk of acute kidney injury was not increased with SGLT2 inhibitor use [<a href="#rid71">71</a>]. In the <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> trial to assess kidney outcomes described above [<a href="#rid6">6</a>], an initial decline in eGFR of up to 30 percent could be seen, presumably due to a reduction in glomerular pressure; however, this initial reduction in eGFR stabilizes over time. Furthermore, in trials that were designed to evaluate cardiovascular morbidity and mortality in patients with type 2 diabetes and established cardiovascular disease (CVD), SGLT2 inhibitors reduced the incidence of worsening nephropathy, suggesting a kidney protective effect. (See <a class="local">'Kidney outcomes'</a> above.)</p><p>Nevertheless, kidney function should be assessed prior to initiation of SGLT2 inhibitors and monitored during treatment. SGLT2 inhibitors should be used with caution in patients with comorbidities that might predispose to acute kidney injury (eg, heart failure, hypovolemia) and in conjunction with other medications that predispose to acute kidney injury (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], ACE inhibitors/ARBs, diuretics). Dose adjustments and more frequent monitoring are required when estimated glomerular filtration rate (eGFR) is &lt;60 mL/min/1.73 m<sup>2</sup>. (See <a class="local">'Dosing'</a> above and <a class="local">'Contraindications and precautions'</a> above.)</p><p class="headingAnchor" id="H2984578296"><span class="h2">Skeletal fragility</span><span class="headingEndMark"> — </span>In some [<a href="#rid72">72,73</a>] studies, the incidence of fractures was higher in patients taking <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>. As an example, in one analysis, there were 1.4 and 1.5 bone fractures per 100 patient-years exposure to canagliflozin 100 mg and 300 mg, respectively, compared with 1.1 per 100 patient-years in the comparator (placebo or active) group [<a href="#rid72">72,73</a>]. Low trauma fractures have been reported as early as 12 weeks after starting the drug. However, other studies have not found increased fracture risk with SGLT2 inhibitors [<a href="#rid6">6,74-76</a>].</p><p>A possible mechanism, particularly for fractures occurring in older individuals after only 12 weeks of therapy, is orthostatic hypotension resulting in postural dizziness and falls. SGLT2 inhibitors may also adversely affect bone density. Bone density studies were performed as part of a two-year, placebo-controlled trial of <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> in 716 older patients. Patients in the canagliflozin compared with control group had progressively greater loss of bone density over time at the total hip (placebo-corrected declines of 0.9 and 1.2 percent for canagliflozin 100 and 300 mg, respectively) and spine (placebo-corrected declines of 0.3 and 0.7 percent, respectively) [<a href="#rid72">72,77,78</a>].</p><p>Although fractures have been reported to occur more frequently only in patients taking <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, based on putative mechanisms, other SGLT2 inhibitors may also reduce bone mass and increase bone fracture risk. A meta-analysis of trials evaluating safety outcomes did not show an increased risk of fracture with <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> or <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> [<a href="#rid79">79</a>]. The increase in fracture with canagliflozin was not significant (odds ratio [OR] 1.15, 95% CI 0.71-1.88). </p><p class="headingAnchor" id="H2627189083"><span class="h2">Diabetic ketoacidosis</span><span class="headingEndMark"> — </span>SGLT2 inhibitors are associated with an increased risk of diabetic ketoacidosis (DKA) [<a href="#rid43">43,80</a>]. In a network meta-analysis of 36 trials that evaluated drug therapies for type 2 diabetes, an increased risk of DKA was found only for SGLT2 inhibitors (OR 2.07, 95% CI 1.44-2.98, versus other therapies) [<a href="#rid44">44</a>]. Similarly, in a population-based cohort study from Canada and the United Kingdom (more than 350,000 patients and 500 DKA events), SGLT2 inhibitors (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>) compared with dipeptidyl peptidase 4 (DPP-4) inhibitors were associated with an increased risk of DKA (incidence 2.03 versus 0.75 per 1000 person-years, respectively, [HR 2.85, 95% CI 1.99-4.08]) [<a href="#rid81">81</a>]. Among the three SGLT2 inhibitors, canagliflozin was associated with the highest risk (HR 3.58 compared with 1.86 and 2.52 for dapagliflozin and empagliflozin, respectively).</p><p>In several studies, "euglycemic" (usually meaning plasma glucose &lt;250 mg/dL) DKA has been reported in patients with type 2 diabetes [<a href="#rid82">82-85</a>]. In these individuals, the absence of substantial hyperglycemia delays recognition of the problem by both the patients and the clinicians. Serum ketones should be obtained in any patient with nausea, vomiting, or malaise while taking SGLT2 inhibitors, and patients should be counseled to withhold therapy until symptoms resolve. SGLT2 inhibitors should be discontinued if acidosis is confirmed [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/1792.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1795.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment"</a>.) </p><p>The risk of SGLT2 inhibitors with regard to DKA has been uniformly demonstrated in placebo-controlled trials in type 1 diabetes. The increased risk for DKA occurred in these studies even though participants at high risk for DKA were excluded at baseline and substantial efforts to mitigate this risk were implemented. Off-label use in type 1 diabetes is therefore discouraged [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus", section on 'Adjunctive therapy not recommended'</a>.)</p><p class="headingAnchor" id="H4228930879"><span class="h2">Amputations</span><span class="headingEndMark"> — </span>Compared with other oral and injectable diabetes agents, SGLT2 inhibitors, particularly <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, are associated with an increased risk of amputation [<a href="#rid44">44,85,88,89</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In two randomized trials evaluating <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> versus placebo in patients with type 2 diabetes and established CVD (or at increased CVD risk) [<a href="#rid5">5,90,91</a>], there was an approximately twofold increased risk of lower limb amputations (predominantly toe and midfoot) in patients taking canagliflozin (amputation incidence 5.9 and 2.8 per 1000 patient-years for patients taking canagliflozin and placebo, respectively, in the first trial, and 7.5 and 4.2 per 1000 patient-years, respectively, in the second trial) [<a href="#rid92">92</a>]. Patients were followed for a mean 5.7 and 2.1 years, respectively. Patients with a history of prior amputation, peripheral vascular disease, and neuropathy were at highest risk for amputation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a pharmacovigilance study of over eight million case safety reports, 79 lower-limb amputations associated with the use of SGLT2 inhibitors were reported since 2013. An increased risk of lower-limb amputations was reported with both <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> (proportional reporting ratio [PRR] 7.09, 95% CI 5.25-9.57) and <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> (PRR 4.96, 95% CI 2.89-8.50), although the absolute number of lower-limb amputations reported was quite low (56 and 14, respectively) [<a href="#rid93">93</a>]. There was a significant increased risk of toe amputations with canagliflozin, empagliflozin, and <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> (PRRs 8.91, 6.86, and 2.62, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in adults with type 2 diabetes and either established CVD or elevated CVD risk, participants randomly assigned to <a class="drug drug_general" data-topicid="140647" href="/d/drug information/140647.html" rel="external">bexagliflozin</a> exhibited a higher risk of lower limb amputations than those who received placebo treatment (amputation incidence 8.3 versus 5.1 events per 1000 patient-years, respectively) [<a href="#rid19">19</a>].</p><p></p><p>In a post hoc analysis of the <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> cardiovascular trial, however, there was no increased risk of lower limb amputation [<a href="#rid94">94</a>]. Similarly, in the kidney outcomes trial, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> was not associated with an increased risk of lower extremity amputation (or fracture) [<a href="#rid6">6</a>]. However, the study was terminated early due to benefit, and due to the findings in prior canagliflozin trials, the protocol was amended to employ a risk mitigation strategy in which a foot exam was performed at every study visit and the study medication was stopped if risk factors for amputation were present. (See <a class="local">'Kidney outcomes'</a> above.)</p><p>SGLT2 inhibitors should be used with caution in patients at risk for foot amputation, including severe neuropathy (loss of protective sensation), foot deformity, vascular disease, and history of previous foot ulceration. Patients taking SGLT2 inhibitors should be monitored for signs and symptoms of foot ulceration. (See  <a class="medical medical_review" href="/d/html/1749.html" rel="external">"Evaluation of the diabetic foot"</a>.)</p><p class="headingAnchor" id="H3053872592"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/140971.html" rel="external">"Society guideline links: Diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H3838014154"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15402.html" rel="external">"Patient education: Type 2 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15595.html" rel="external">"Patient education: Treatment for type 2 diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1737.html" rel="external">"Patient education: Type 2 diabetes: Treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1744.html" rel="external">"Patient education: Glucose monitoring in diabetes (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1741.html" rel="external">"Patient education: Preventing complications from diabetes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2124493672"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – The sodium-glucose cotransporter 2 (SGLT2) is expressed in the proximal tubule and mediates reabsorption of approximately 90 percent of the filtered glucose load. SGLT2 inhibitors promote the renal excretion of glucose and thereby modestly lower elevated blood glucose levels in patients with type 2 diabetes. They do not usually cause hypoglycemia in the absence of therapies that otherwise cause hypoglycemia. SGLT2 inhibitors decrease blood pressure and weight. (See <a class="local">'Mechanism of action'</a> above and <a class="local">'Glycemic efficacy'</a> above and <a class="local">'Weight loss'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – SGLT2 inhibitors are not considered as initial therapy for the majority of patients with type 2 diabetes. In patients with cardiovascular or kidney comorbidities, many SGLT2 inhibitors have demonstrated benefit for cardiovascular and kidney outcomes, and therefore they are appropriate to use in combination with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (and/or another oral agent) in this setting. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atherosclerotic cardiovascular disease (CVD)</strong> – When a decision has been made to use an SGLT2 inhibitor in a patient with type 2 diabetes and atherosclerotic CVD, we suggest <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, rather than another SGLT2 inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). This is based on the results of the empagliflozin and cardiovascular outcomes trial. Although <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a> also showed cardiovascular benefits, there was an increase in the risk of lower limb amputations and fractures in canagliflozin-treated patients that was not observed in trials of empagliflozin (or <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>). In the primary analysis, dapagliflozin did not appear to reduce atherosclerotic cardiovascular morbidity or cardiovascular mortality; however, it decreased cardiovascular outcomes in a subanalysis of the primary trial. <a class="drug drug_general" data-topicid="116180" href="/d/drug information/116180.html" rel="external">Ertugliflozin</a> was not superior to placebo in reducing the primary composite cardiovascular endpoint. (See <a class="local">'Choice of therapy'</a> above and <a class="local">'Cardiovascular effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart failure or kidney disease</strong> – In patients with type 2 diabetes and heart failure and/or kidney disease, all SGLT2 inhibitors have shown salutary effects; choice of agent is primarily dictated by provider preference, insurance formulary restrictions, kidney function, and cost. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Without cardiovascular or kidney disease</strong> – In patients without cardiovascular or kidney disease, SGLT2 inhibitors in general may have a role as a second or third agent in those whom glucagon-like peptide 1 (GLP-1)-based therapies are contraindicated and increasing insulin dosing would lead to weight gain, in those who cannot or will not take insulin, in patients in whom risk of hypoglycemia is high (frail, older adults), or in whom avoidance of weight gain is a priority. The choice of SGLT2 inhibitor is also often dictated by cost and insurer formulary preference. (See <a class="local">'Patient selection'</a> above and <a class="local">'Choice of therapy'</a> above and  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Dual agent failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications and precautions</strong> – We avoid use of SGLT2 inhibitors in patients with a history of diabetic ketoacidosis (DKA). We use them with caution in patients with frequent bacterial urinary tract infections or genitourinary yeast infections, low bone density and high risk for falls and fractures, foot ulceration, or factors predisposing to DKA (eg, pancreatic insufficiency, drug or alcohol abuse disorder, ketogenic diets) because of increased risk while using these agents. (See <a class="local">'Contraindications and precautions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Volume status and kidney function (serum creatinine with estimation of glomerular filtration rate [eGFR]) should be assessed prior to starting an SGLT2 inhibitor and periodically thereafter. Patients taking SGLT2 inhibitors should be monitored for signs and symptoms of genitourinary tract infections, foot ulceration, and DKA. (See <a class="local">'Pretreatment evaluation'</a> above and <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of SGLT2 inhibitors are vulvovaginal candidal infections and hypotension. Acute kidney injury, urinary tract infections, necrotizing fasciitis of the perineum, euglycemic DKA, increased risk of lower extremity amputation, and bone fractures have also been reported. (See <a class="local">'Adverse effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383:1436.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347.</a></li><li><a class="nounderline abstract_t">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Cherney DZI, Charbonnel B, Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 2021; 64:1256.</a></li><li><a class="nounderline abstract_t">Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA 2016; 316:313.</a></li><li><a class="nounderline abstract_t">de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45:3075.</a></li><li><a class="nounderline abstract_t">Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016; 18:783.</a></li><li><a class="nounderline abstract_t">Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 2016; 6:e009417.</a></li><li class="breakAll">National Institutes of Health - DailyMed: Invokana http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3#section-8.6 (Accessed on May 22, 2013).</li><li><a class="nounderline abstract_t">Canaglifozin (Invokana) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:37.</a></li><li class="breakAll">http://www.invokanahcp.com/prescribing-information.pdf (Accessed on May 22, 2013).</li><li class="breakAll">http://ec.europa.eu/health/documents/community-register/2012/20121112124487/anx_124487_en.pdf (Accessed on May 22, 2013).</li><li class="breakAll">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm (Accessed on January 09, 2014).</li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s000lbl.pdf (Accessed on September 18, 2015).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf (Accessed on January 08, 2018).</li><li class="breakAll">Bexagliflozin prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44:375.</a></li><li><a class="nounderline abstract_t">Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15:372.</a></li><li><a class="nounderline abstract_t">Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37:1815.</a></li><li><a class="nounderline abstract_t">Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2:691.</a></li><li><a class="nounderline abstract_t">Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab 2018; 20:1111.</a></li><li><a class="nounderline abstract_t">Hollander P, Liu J, Hill J, et al. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Ther 2018; 9:193.</a></li><li><a class="nounderline abstract_t">Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 2018; 20:520.</a></li><li><a class="nounderline abstract_t">Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab 2018; 20:530.</a></li><li class="breakAll">US Food and Drug Administration. FDA News Release: FDA approves Invokana to treat type 2 diabetes, March 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm (Accessed on April 10, 2013).</li><li class="breakAll">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm (Accessed on August 06, 2014).</li><li class="breakAll">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=209803 (Accessed on January 08, 2018).</li><li><a class="nounderline abstract_t">Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159:262.</a></li><li><a class="nounderline abstract_t">Sun YN, Zhou Y, Chen X, et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 2014; 4:e004619.</a></li><li><a class="nounderline abstract_t">Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. J Diabetes Complications 2015; 29:1295.</a></li><li><a class="nounderline abstract_t">Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34:2015.</a></li><li><a class="nounderline abstract_t">Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156:405.</a></li><li><a class="nounderline abstract_t">Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36:2508.</a></li><li><a class="nounderline abstract_t">Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382:941.</a></li><li><a class="nounderline abstract_t">Halvorsen YD, Lock JP, Zhou W, et al. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab 2019; 21:2248.</a></li><li><a class="nounderline abstract_t">Halvorsen YC, Walford GA, Massaro J, et al. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes Obes Metab 2019; 21:2496.</a></li><li><a class="nounderline abstract_t">Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation 2019; 139:2516.</a></li><li><a class="nounderline abstract_t">Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 2019; 139:2022.</a></li><li><a class="nounderline abstract_t">Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021; 10:CD013650.</a></li><li><a class="nounderline abstract_t">Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 2022; 65:2000.</a></li><li><a class="nounderline abstract_t">Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2023; 381:e074068.</a></li><li><a class="nounderline abstract_t">Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383:1425.</a></li><li class="breakAll">Bexagliflozin efficacy and safety trial (BEST). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02558296 (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393:31.</a></li><li><a class="nounderline abstract_t">Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383:1413.</a></li><li><a class="nounderline abstract_t">Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation 2020; 141:1227.</a></li><li><a class="nounderline abstract_t">McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381:1995.</a></li><li><a class="nounderline abstract_t">Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400:1788.</a></li><li><a class="nounderline abstract_t">Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375:323.</a></li><li><a class="nounderline abstract_t">Inzucchi SE, Wanner C, Hehnke U, et al. Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. Diabetes Care 2019; 42:e53.</a></li><li><a class="nounderline abstract_t">Li C, Zhou Z, Neuen BL, et al. Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2021; 23:252.</a></li><li><a class="nounderline abstract_t">Ma Y, Lin C, Cai X, et al. The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2022; 15:877.</a></li><li><a class="nounderline abstract_t">Zhou B, Shi Y, Fu R, et al. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne) 2022; 13:907340.</a></li><li><a class="nounderline abstract_t">Yen FS, Wei JC, Yu TS, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Netw Open 2023; 6:e2348431.</a></li><li><a class="nounderline abstract_t">Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012; 9:117.</a></li><li><a class="nounderline abstract_t">Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28:1173.</a></li><li><a class="nounderline abstract_t">Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11:43.</a></li><li><a class="nounderline abstract_t">Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19:348.</a></li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm (Accessed on December 10, 2015).</li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm (Accessed on September 05, 2018).</li><li><a class="nounderline abstract_t">Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabet Med 2017; 34:1646.</a></li><li><a class="nounderline abstract_t">Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med 2019; 170:764.</a></li><li><a class="nounderline abstract_t">Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013; 6:453.</a></li><li><a class="nounderline abstract_t">Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014; 16:875.</a></li><li class="breakAll">https://www.invokanahcp.com/prescribing-information.pdf (Accessed on September 16, 2015).</li><li class="breakAll">Invokana (canagliflozin). US FDA approved product information; Titusville, NJ: Janssen Pharmaceuticals, Inc; May 2016. (Available online at www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s015s019lbl.pdf (accessed May 31, 2016)).</li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm (Accessed on June 17, 2016).</li><li><a class="nounderline abstract_t">Nadkarni GN, Ferrandino R, Chang A, et al. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care 2017; 40:1479.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm (Accessed on September 14, 2015).</li><li><a class="nounderline abstract_t">Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2016; 101:157.</a></li><li><a class="nounderline abstract_t">Fralick M, Kim SC, Schneeweiss S, et al. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med 2019; 170:155.</a></li><li><a class="nounderline abstract_t">Zhuo M, Hawley CE, Paik JM, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open 2021; 4:e2130762.</a></li><li><a class="nounderline abstract_t">Wang X, Zhang F, Zhang Y, et al. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos Int 2023; 34:2013.</a></li><li><a class="nounderline abstract_t">Alba M, Xie J, Fung A, Desai M. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 2016; 32:1375.</a></li><li><a class="nounderline abstract_t">Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. J Clin Endocrinol Metab 2016; 101:44.</a></li><li><a class="nounderline abstract_t">Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 2016; 18:1199.</a></li><li><a class="nounderline abstract_t">Liu J, Li L, Li S, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020; 22:1619.</a></li><li><a class="nounderline abstract_t">Douros A, Lix LM, Fralick M, et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Ann Intern Med 2020; 173:417.</a></li><li><a class="nounderline abstract_t">Peters AL, Buschur EO, Buse JB, et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015; 38:1687.</a></li><li><a class="nounderline abstract_t">Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complications 2016; 30:1162.</a></li><li><a class="nounderline abstract_t">Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017; 376:2300.</a></li><li><a class="nounderline abstract_t">Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018; 363:k4365.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm (Accessed on June 18, 2015).</li><li><a class="nounderline abstract_t">Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100:2849.</a></li><li><a class="nounderline abstract_t">Chang HY, Singh S, Mansour O, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med 2018; 178:1190.</a></li><li><a class="nounderline abstract_t">Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ 2020; 370:m2812.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 2013; 166:217.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab 2017; 19:387.</a></li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm (Accessed on May 17, 2017).</li><li><a class="nounderline abstract_t">Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab 2018; 20:1531.</a></li><li><a class="nounderline abstract_t">Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. Diabetes Care 2018; 41:e4.</a></li></ol></div><div id="topicVersionRevision">Topic 109245 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23087012" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970396" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dapagliflozin in Patients with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415602" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26378978" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605608" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33665685" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434443" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36189689" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059700" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911584" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911584" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669782" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Canaglifozin (Invokana) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21495788" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279307" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24929430" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24948511" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29266675" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282633" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28857451" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28921862" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28921862" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28921862" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28921862" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026259" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24710132" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26365905" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21816980" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431673" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23564919" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23850055" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31161692" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31297965" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882239" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786725" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34693515" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35925319" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37024129" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966714" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966714" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30424892" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865377" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31983236" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31535829" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36351458" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27299675" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30705060" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32954617" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35839519" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35692406" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38117497" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22381403" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effects of SGLT2 inhibitors on cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22632452" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425012" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862830" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862830" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862830" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28887847" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31060053" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24348059" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : SGLT-2 inhibitors and their potential in the treatment of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329038" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329038" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329038" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329038" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827404" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827404" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580237" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30597484" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34705014" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37695339" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27046479" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580234" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27407013" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364674" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32716707" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26078479" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240541" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591538" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429124" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429124" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26086329" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : SGLT2 Inhibitors May Predispose to Ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30105373" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32843476" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23895803" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28120497" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28120497" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29430814" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133344" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
